Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies
Metrics: PDF 914 views | HTML 1406 views | ?
Yuanyuan Feng1,*, Lihong Zhou1,*, Xiaoting Sun1 and Qi Li1
1 Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
* These authors have contributed in equal measure as the first author
Qi Li, email:
Keywords: HIPK2; cancer; p53; apoptosis; angiogenesis
Received: September 02, 2016 Accepted: January 04, 2017 Published: January 18, 2017
The HIPK2 (serine/threonine homeodomain-interacting protein kinase 2) is a “caretaker” gene, its inactivation increases tumorigenicity while its activation inhibits tumor growth. This report reviews the anti-tumorigenic mechanisms of HIPK2, which include promotion of apoptosis, inhibition of angiogenesis in hypoxia, prevention of tumor invasion/metastasis and attenuation of multidrug resistance in cancer. Additionally, we summarize conditions or factors that may increase HIPK2 activity.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.